Table 1. Basic characteristics of GnRHa users and nonusers.
| Characteristics | GnRHa users (n = 2,053) | GnRHa nonusers (n = 2,654) | P value | |
|---|---|---|---|---|
| Age at diagnosis, yr | < 0.001 | |||
| < 55 | 53 (2.6) | 246 (9.3) | ||
| 55–64 | 277 (13.5) | 785 (29.6) | ||
| 65–74 | 806 (39.2) | 1,107 (41.7) | ||
| ≥ 75 | 917 (44.7) | 516 (19.4) | ||
| Residence | 0.002 | |||
| Urban | 1,552 (75.6) | 2,116 (79.7) | ||
| Suburban/rural | 501 (24.4) | 538 (20.3) | ||
| Insurance type | < 0.001 | |||
| NHI | 1,933 (94.2) | 2,571 (96.9) | ||
| Medicaid | 120 (5.8) | 83 (3.1) | ||
| Prior medication use | ||||
| Statin | 140 (6.8) | 219 (8.3) | 0.035 | |
| Antihypertensive | 203 (9.9) | 318 (12.0) | 0.017 | |
| Anticoagulant | 185 (9.0) | 348 (13.1) | < 0.001 | |
| Antiplatelet | 91 (4.4) | 101 (3.8) | 0.457 | |
| Prior antiandrogen use | 330 (16.0) | 0 (0.0) | - | |
| Medical history | ||||
| Hypertension | 896 (43.6) | 1,126 (42.4) | 0.344 | |
| DM | 454 (22.1) | 592 (22.3) | 0.420 | |
| Liver disease | 56 (2.7) | 89 (3.4) | 0.112 | |
| Other cancer | 243 (11.8) | 280 (10.6) | 0.211 | |
| Chronic kidney disease | 52 (2.5) | 48 (1.8) | 0.079 | |
| COPD | 188 (9.2) | 252 (9.4) | 0.767 | |
| Asthma | 158 (7.7) | 176 (6.6) | 0.135 | |
| Peripheral vascular disease | 220 (10.7) | 277 (10.4) | 0.679 | |
| Other treatment | < 0.001 | |||
| Radical prostatectomy | 0 (0.0) | 1,603 (60.4) | ||
| Radiotherapy | 458 (22.3) | 517 (19.5) | ||
| Charlson comorbidity index | < 0.001 | |||
| 0, 1 | 116 (5.7) | 414 (15.6) | ||
| 2 | 341 (16.6) | 713 (26.9) | ||
| 3 | 687 (33.5) | 772 (29.1) | ||
| 4 | 510 (24.8) | 431 (16.2) | ||
| ≥ 5 | 399 (19.4) | 328 (12.4) | ||
Data are presented as number (%).
GnRHa = gonadotropin-releasing hormone agonist, COPD = chronic obstructive pulmonary disease, NHI = national health insurance, DM = diabetes mellitus.